Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

被引：0

作者：

Rosinol, Laura ^{[1
]}

Oriol, Albert ^{[2
]}

Isabel Teruel, Ana ^{[3
]}

Hernandez, Dolores ^{[4
]}

Jesus Blanchard, M. ^{[5
]}

De La Rubia, Javier ^{[6
]}

Granell, Miquel ^{[7
]}

Besalduch, Juan ^{[8
]}

Palomera, Luis ^{[9
]}

Gonzalez, Yolanda ^{[10
]}

Asuncion Echebeste, M. ^{[11
]}

Diaz-Mediavilla, Joaqun ^{[12
]}

Hernandez, Miguel T. ^{[13
]}

de Arriba, Felipe ^{[14
]}

Carmen Gutierrez, Norma ^{[15
]}

Luisa Martin-Ramos, M. ^{[16
]}

Teresa Cibeira, M. ^{[17
]}

Victoria Mateos, Maria ^{[15
]}

Martinez-Lopez, Joaquin ^{[16
]}

Alegre, Adrian ^{[18
]}

Lahuerta, Juan Jose ^{[16
]}

San Miguel, Jesus F. ^{[19
]}

Blade, Joan ^{[20
]}

机构：

[1] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, Amyloidosis & Myeloma Unit, Barcelona, Spain

[2] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[3] Hosp Clin Univ Valencia, Valencia, Spain

[4] Hosp Univ La Paz, Madrid, Spain

[5] Hosp Ramon & Cajal, E-28034 Madrid, Spain

[6] Hosp Univ La Fe, Valencia, Spain

[7] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[8] Univ Hosp Son Espases, Palma De Mallorca, Spain

[9] Hosp Lozano Blesa, Zaragoza, Spain

[10] ICO Dr Josep Trueta, Girona, Spain

[11] Hosp Donostia, Donostia San Sebastian, Spain

[12] Hosp Clin Madrid, Madrid, Spain

[13] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain

[14] Hosp Morales Messeguer, Murcia, Spain

[15] Hosp Univ Salamanca, Salamanca, Spain

[16] Hosp Univ 12 Octubre, Madrid, Spain

[17] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[18] Hosp Univ Princesa, Madrid, Spain

[19] Univ Navarra Clin, Pamplona, Spain

[20] Hosp Clin Barcelona, Barcelona, Spain

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study
Rosinol Dachs, Laura
Oriol, Albert
Isabel Teruel, Ana
Lopez de la Guia, Ana
Jesus Blanchard, M.
Jarque, Isidro
Granell, Miquel
Sampol, Antonia
Palomera, Luis
Gonzalez-Montes, Yolanda
Bengoechea, Enrique
Martinez-Martinez, Rafael
Hernandez, Miguel T.
De Arriba, Felipe
Luisa Martin-Ramos, Maria
Gutierrez, Norma C.
Teresa Cibeira, Maria
Mateos, Maria-Victoria
Martinez-Lopez, Joaquin
Alegre, Adrian
Jose Lahuerta, Juan
San-Miguel, Jesus F.
Blade, Joan
[J]. BLOOD, 2018, 132
[2] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Rosinol, Laura
Oriol, Albert
Isabel Teruel, Ana
Hernandez, Dolores
Lopez-Jimenez, Javier
de la Rubia, Javier
Granell, Miquel
Besalduch, Joan
Palomera, Luis
Gonzalez, Yolanda
Asuncion Etxebeste, Ma
Diaz-Mediavilla, Joaquin
Hernandez, Miguel T.
de Arriba, Felipe
Gutierrez, Norma C.
Luisa Martin-Ramos, Ma
Teresa Cibeira, Ma
Victoria Mateos, Ma
Martinez, Joaquin
Alegre, Adrian
Jose Lahuerta, Juan
San Miguel, Jesus
Blade, Joan
[J]. BLOOD, 2012, 120 (08) : 1589 - 1596
[3] RANDOMIZED PHASE 2 STUDY OF BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE WITH OR WITHOUT CYCLOPHOSPHAMIDE AS INDUCTION THERAPY IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM): LONG-TERM FOLLOW-UP RESULTS
Ludwig, H.
Greil, R.
Masszi, T.
Spicka, I.
Shpilberg, O.
Hajek, R.
Dmoszynska, A.
Paiva, B.
Vidriales, M. B.
Esteves, G.
Stoppa, A. M.
Robinson, D., Jr.
Chaturvedi, S.
Ataman, O.
Enny, C.
Feng, H.
van de Velde, H.
[J]. HAEMATOLOGICA, 2014, 99 : 112 - 113
[4] A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib
Rosinol, Laura
Teresa Cibeira, Maria
Victoria Mateos, Maria
Martinez, Joaquin
Oriol, Albert
Isabel Teruel, Ana
Hernandez, Dolores
Garcia-Larana, Jose
De La Rubia, Javier
Sureda, Anna
Besalduch, Juan
Palomera, Luis
Gonzalez, Yolanda
Asuncion Etxebeste, Maria
Diaz-Media-villa, Joaquin
Hernandez, Miguel T.
de Arriba, Felipe
Alegre, Adrian
Jose Lahuerta, Juan
San Miguel, Jesus F.
Blade, Joan
[J]. BLOOD, 2010, 116 (21) : 139 - 140
[5] Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma
Lee, Yoojin
Kim, Kihyun
Sohn, Sang Kyun
Back, Dongwon
Moon, Joon Ho
Lee, Je-Jung
Jo, Jae-Cheol
Lee, Won-Sik
Shin, Ho-Jin
Kim, Sung-Hyun
Lee, Ji Hyun
Bae, Sung Hwa
Kim, Min Kyoung
Lee, Ho Sup
Min, Chang-Ki
[J]. BLOOD, 2018, 132
[6] Bortezomib-Thalidomide-Dexamethasone (VTD) as salvage treatment in patients with Multiple Myeloma eligible for transplantation in the real world. Long-term follow-up.
Vasquez, Jule
Quintana, Shirley
Alcarraz, Cindy
Villena, Marco
Vidaurre, Tatiana
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S162 - S163
[7] Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma.
Jagannath, Sundar
Durie, Brian G. M.
Wolf, Jeffrey Lee
Camacho, Elber S.
Irwin, David
Lutzky, Jose
McKinley, Marti
Gabayan, Afshin Eli
Mazumder, Amitabha
Crowley, John
Vescio, Robert
[J]. BLOOD, 2006, 108 (11) : 238A - 239A
[8] LONG-TERM FOLLOW-UP AND THERAPY IN MULTIPLE MYELOMA
VELEZGAR.E
MALDONADO, N
[J]. CANCER, 1971, 27 (01) : 44 - +
[9] Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma
Ludwig, Heinz
Viterbo, Luisa
Greil, Richard
Masszi, Tamas
Spicka, Ivan
Shpilberg, Ofer
Hajek, Roman
Dmoszynska, Anna
Paiva, Bruno
Vidriales, Maria-Belen
Esteves, Graca
Stoppa, Anne Marie
Robinson, Don, Jr.
Ricci, Deborah
Cakana, Andrew
Enny, Christopher
Feng, Huaibao
van de Velde, Helgi
Harousseau, Jean-Luc
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 247 - 255
[10] Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Joseph, Nisha S.
Kaufman, Jonathan L.
Dhodapkar, Madhav, V
Hofmeister, Craig C.
Almaula, Dhwani K.
Heffner, Leonard T.
Gupta, Vikas A.
Boise, Lawrence H.
Lonial, Sagar
Nooka, Ajay K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (17) : 1928 - +

← 1 2 3 4 5 →